A Peek Into Today’s Analysts Ratings (CVH, ONXX, PRXL, SBUX, WU, WYN, PSYS, UAM, VRUS)

Some of today’s upgrades, downgrades and initiations are:

Upgrades

Goldman upgraded Coventry Health (NYSE: CVH) from “sell” to “neutral.” The upgrade in the rating is based on valuation, according to Goldman. CVH’s shares lost 1.25% in after hours trading.

Analysts at Goldman upgraded Onyx Pharmaceuticals (NASDAQ: ONXX) from “neutral” to “buy.” The price target for ONXX is set to $37. Goldman said that ONXX has an impressive pipeline, apart from being an attractive acquisition target. ONXX jumped 5.94% to $33.37 at 9:33 am.

Parexel (NASDAQ: PRXL) upgraded at Goldman to “buy.” Goldman said that PRXL has the potential to deliver above-average earnings growth. PRXL added 3.76% at 9:34am.

UBS upgraded Starbucks (NASDAQ: SBUX) from “neutral” to “buy.” The price target for SBUX is set to $29. UBS has also raised its estimates for the company, given its strong sales and earnings momentum.

Downgrade

Analysts at William Blair downgraded Western Union (NYSE: WU) from “outperform to “market perform.” William Blair said that there are no catalysts for WU’s stock.

Wyndham Worldwide (NYSE: WYN) downgraded at Goldman from “buy” to “neutral.” Goldman mentions that the call is based on valuation, given that the target price for WYN is set to $26.

Wells Fargo downgraded Psychiatric Solutions (NASDAQ: PSYS) from “outperform” to “market perform.” According to Wells Fargo, PSYS’s stock already reflects a potential buyout.

Universal American (NYSE: UAM) downgraded at Goldman from “neutral” to “sell.” Goldman also added UAM’s stock to Conviction List based on valuation.

Initiate

Citi initiated coverage of Pharmasset (NASDAQ: VRUS) with a “buy” rating. The target price for VRUS is set to $34. Citi expects VRUS’ RG7128 product to become a major drug in the hepatitis C market.

More Analyst Ratings here